QQQ   422.83 (-0.14%)
TSLA   149.20 (-0.49%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
QQQ   422.83 (-0.14%)
TSLA   149.20 (-0.49%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
QQQ   422.83 (-0.14%)
TSLA   149.20 (-0.49%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
QQQ   422.83 (-0.14%)
TSLA   149.20 (-0.49%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
Free Trial
NASDAQ:CYTR

LadRx (CYTR) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)
Free CYTR Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.09
▼
$0.10
52-Week Range
N/A
Volume
4,000 shs
Average Volume
99,706 shs
Market Capitalization
$4.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
CYTR stock logo

About LadRx Stock (NASDAQ:CYTR)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

CYTR Stock News Headlines

May 17, 2023 | investing.com
LadRx (LADX) Earnings Dates & Reports
March 29, 2023 | stockhouse.com
LadRx Highlights Patent Issued for Its LADR Technology
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
October 5, 2022 | finance.yahoo.com
LadRx Corporation Announces OTCQB Ticker Change to LADX
September 23, 2022 | finance.yahoo.com
CytRx Corporation Relaunches as LadRx Corporation
September 8, 2022 | seekingalpha.com
European patent office awards CytRx patent for LADR platform
September 7, 2022 | finance.yahoo.com
European Patent Office Awards CytRx Key Patent
August 3, 2022 | marketwatch.com
Temperature Data logger Market Size: Market Growth at a CAGR of 3.64% to Outstrip USD 1364.75 Million by 2028
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
August 2, 2022 | thestreet.com
Whiplash: S&P Veers to All-Time High Before Crashing
May 19, 2022 | finance.yahoo.com
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
May 18, 2022 | marketwatch.com
Kinase Inhibitors Market Report [2022]- Historical, Current, and Projected Size, in terms of value
See More Headlines
Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Manufacturing
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTR
CUSIP
N/A
CIK
N/A
Web
www.cytrx.com
Phone
(310) 826-5648
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
45,037,000
Free Float
N/A
Market Cap
$4.14 million
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Stephen Snowdy
    Chief Executive Officer
  • John Y. Caloz
    Chief Financial Officer, Treasurer & Senior VP
  • Felix Kratz
    Vice President-Drug Discovery
  • Cristina Newman
    Secretary

Key Competitors

View All Competitors

This page (NASDAQ:CYTR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research